Relationship of pentraxin 3 with insulin sensitivity in gestational diabetes

European Journal of Clinical Investigation

Volumn 43, Issue 4, 2013, Pages 341-349

  Todoric, Jelena ^a   Handisurya, Ammon ^a   Knapp, Bernhard ^a   Tura, Andrea ^b   Pacini, Giovanni ^b   Kautzky Willer, Alexandra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CNR   (Italy)

Author keywords

Acute hyperglycaemia; Gestational diabetes; Inflammatory markers; Insulin resistance; Oral glucose tolerance test; Pentraxin 3

Indexed keywords

C PEPTIDE; GLUCOSE; PENTRAXIN 3;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; PREGNANCY; REGRESSION ANALYSIS; SERUM AMYLOID P-COMPONENT;

EID: 84875373695     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12051     Document Type: Article

References (39)

1. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
2. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
3. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ et al. Structure of pentameric human serum amyloid P component. Nature 1994;367:338-45.
4. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003;33:2886-93.
5. Breviario F. d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-7.
6. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004;175:221-8.
7. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F et al. Characterization of the long pentraxin PTX3 as a TNFα-induced secreted protein of adipose cells. J Lipid Res 2006;44:994-1000.
8. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:10-14.
9. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55.
10. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54.
11. Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005;28:1965-73.
12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46. Review.
13. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
14. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A et al. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010;42:8-13.
15. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009;29:594-9.
16. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-91. Review.
17. Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes. Obstet Gynecol Clin North Am 2007;34:213-24.
18. Wolf M, Sauk J, Shah A. Vossen Smirnakis K, Jimenez-Kimble R, Ecker JL. Inflammation and glucose tolerance: a prospective study of gestational diabetes mellitus. Diabetes Care 2004;27:21-7.
19. Ategbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006;91:4137-43.
20. Georgiou HM, Lappas M, Georgiou GM, Marita A, Bryant VJ, Hiscock R et al. Screening for biomarkers predictive of gestational diabetes mellitus. Acta Diabetol 2008;45:157-65.
21. Zhou P, Luo X, Qi HB, Zong WJ, Zhang H, Liu DD et al. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res 2012; 61:1005-12.
22. Castiglioni MT, Scavini M, Cavallin R, Pasi F, Rosa S, Sabbadini MG et al. Elevation of plasma levels of the long pentraxin 3 precedes preeclampsia in pregnant patients with type 1 diabetes. Autoimmunity 2009;42:296-8.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 2009;32(Suppl. 1):S62-7.
24. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
25. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-109.
26. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48.
27. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
28. Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2006;194:1347-53.
29. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005;7:1-8.
30. Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
31. Fazzini F, Peri G, Doni A. Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-50.
32. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O et al. Plasma pentraxin 3 in chronic kidney disease patients: association with renal function, protein-energy wasting, cardiovascular disease and mortality. Clin J Am Soc Nephrol 2007;2:889-97.
33. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008;4:976-85.
34. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011;6:785-92.
35. Esposito K, Giugliano D, Nappo F, Marfella R. Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19.
36. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D. Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 2009;32(Suppl 2):S373-7.
37. Montelongo A, Lasunción MA, Pallardo LF, Herrera E. Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. Diabetes 1992;41:1651-9.
38. Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009;9:243-8.
39. Kuhl C, Faber OK, Hornnes P, Jensen SL. C-peptide metabolism and the liver. Diabetes 1978;27(Suppl 1):197-200.